Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions

Bibliography

• VARADHACHARY G, AJANI JA: Gastric cancer. Clin. Adv. Hematol. Oncol. (2005) 3(2):118-124.
   PubMedGoogle Scholar
• CREW KD, NEUGUT AI: Epidemiology of gastric cancer. World J. Gastroenterol. (2006) 12(3):354-362.
   PubMed Web of Science ®Google Scholar
• PERA M: Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. (2000) 155:1-14.
   PubMedGoogle Scholar
• HOCHWALD SN, KIM S, KLIMSTRA DS, BRENNAN MF, KARPEH MS: Analysis of 154 actual 5-year survivors of gastric cancer. J. Gastrointest. Surg. (2000) 4(5):520-525.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI T, WATANABE A, SAWADA H et al.: Characteristics and clinical outcome of proximal-third gastric cancer. J. Am. Coll. Surg. (1998) 187(4):352-357.
   PubMed Web of Science ®Google Scholar
• KIM DY, JOO JK, PARK YK, RYU SY, KIM YJ, SIM SK: Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection. Langenbecks Arch. Surg. (2007) 392(2):131-134.
   PubMed Web of Science ®Google Scholar
• MARUYAMA M, TAKESHITA K, ENDO M, DEAKIN M, MOOSSA A: Clinicopathological study of gastric carcinoma in high- and low-mortality countries: comparison between Japan and the US. Gastric Cancer (1998) 1(1):64-70.
   PubMedGoogle Scholar
• WANG HH, ANTONIOLI DA, GOLDMAN H: Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum. Pathol. (1986) 17(5):482-487.
   PubMed Web of Science ®Google Scholar
• FENOGLIO-PREISER CM, WANG J, STEMMERMANN GN, NOFFSINGER A: TP53 and gastric carcinoma: a review. Hum. Mutat. (2003) 21(3):258-270.
   PubMed Web of Science ®Google Scholar
• ALBINO AP, JAEHNE J, ALTORKI N et al.: Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. Eur. J. Surg. Oncol. (1995) 21(1):56-60.
   PubMedGoogle Scholar
• EL-RIFAI W, POWELL SM: Molecular biology of gastric cancer. Semin. Radiat. Oncol. (2002) 12(2):128-140.
   PubMed Web of Science ®Google Scholar
• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• WAGNER AD, GROTHE W, HAERTING J, KLEBER G, GROTHEY A, FLEIG WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. (2006) 24(18):2903-2909.
   PubMed Web of Science ®Google Scholar
• KHAMLY K, JEFFORD M, MICHAEL M, ZALCBERG J: Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opin. Investig. Drugs (2006) 15(2):131-153.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, RAO S, STARLING N et al.: Randomised multicentre Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):LBA4017.
   Google Scholar
• AL-BATRAN S, HARTMANN J, PROBST S et al.: A randomized Phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):LBA4016.
   Google Scholar
• VAN CUTSEM E, MOISEYENKO VM, TJULANDIN S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. (2006) 24(31):4991-4997.
   PubMed Web of Science ®Google Scholar
• RICHARDS DA, WILFONG L, REZNICK D et al.: Phase II multicenter trial of docetaxel+oxaliplatin in stage IV gastroesophageal and/or stomach cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):4071 (Abstract).
   Google Scholar
• MACDONALD JS, SMALLEY SR, BENEDETTI J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. (2001) 345(10):725-730.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, ALLUM WH, STENNING SP et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. (2006) 355(1):11-20.
   PubMed Web of Science ®Google Scholar
• AJANI JA: Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. (2006) 33(Suppl. 1):117-120.
   PubMedGoogle Scholar
• KIM JH, LEE KW, JUNG Y et al.: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci. (2005) 96(6):365-371.
   PubMed Web of Science ®Google Scholar
• BAJETTA E, CELIO L, BUZZONI R et al.: Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann. Oncol. (2003) 14(10):1543-1538.
   PubMed Web of Science ®Google Scholar
• KIM HK, SONG KS, PARK YS et al.: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur. J. Cancer (2003) 39(2):184-191.
   PubMed Web of Science ®Google Scholar
• BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. (1993) 53(19):4727-4735.
   PubMed Web of Science ®Google Scholar
• TIAN X, SONG S, WU J, MENG L, DONG Z, SHOU C: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem. Biophys. Res. Commun. (2001) 286(3):505-512.
   PubMed Web of Science ®Google Scholar
• CHAE Y, KIM J, BAEK J et al.: Vascular endothelial growth factor (VEGF) -460T > C polymorphism is associated with prognosis of patients with early stage gastric cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):4019 (Abstract).
   Google Scholar
• SHAH MA, RAMANATHAN RK, ILSON D et al.: Final results of a multicenter Phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI 6447). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S: June 20 Supplement):4020 (Abstract).
   Google Scholar
• KNOWLES ID, RAMAGE AG: Evidence for a role for central 5-HT2B as well as 5-HT2A receptors in cardiovascular regulation in anaesthetized rats. Br. J. Pharmacol. (1999) 128(3):530-542.
   PubMed Web of Science ®Google Scholar
• BOKU N, OHTSU A, SHIMADA Y et al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. (1999) 17(1):319-323.
   PubMed Web of Science ®Google Scholar
• LAU SC, ROSA DD, JAYSON G: Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis. Curr. Opin. Mol. Ther. (2005) 7(5):493-501.
   PubMed Web of Science ®Google Scholar
• ROJO F, ALBANELL J, SAULEDA S, BASELGA J: Characterization of epidermal growth factor (EGF) receptor and transforming growth factor (TGF)-α expression in gastric cancer and its association with activation of mitogen-activated protein kinase (MAPK). Proc. Am. Soc. Clin. Oncol. (2001) 20:1717 (Abstract).
   Google Scholar
• KOPP R, RUGE M, ROTHBAUER E et al.: Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res. (2002) 22(2B):1161-1167.
   PubMed Web of Science ®Google Scholar
• GARCIA I, VIZOSO F, MARTIN A et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. (2003) 10(3):234-241.
   PubMed Web of Science ®Google Scholar
• KIM T: Technology evaluation: Matuzumab, Merck KGaA. Curr. Opin. Mol. Ther. (2004) 6(1):96-103.
   PubMed Web of Science ®Google Scholar
• YONEMURA Y, NINOMIYA I, OHOYAMA S et al.: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer (1991) 67(11):2914-2918.
   PubMed Web of Science ®Google Scholar
• TANNER M, HOLLMENM, JUNTILA TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. (2005) 16(2):273-278.
   PubMed Web of Science ®Google Scholar
• OUGOLKOV A, YAMASHITA K, BILIM V, TAKAHASHI Y, MAI M, MINAMOTO T: Abnormal expression of E-cadherin, β-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. Int. J. Colorectal Dis. (2003) 18(2):160-166.
   PubMed Web of Science ®Google Scholar
• MULLER-TIDOW C, SCHWABLE J, STEFFEN B et al.: High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res. (2004) 10(4):1241-1249.
   PubMed Web of Science ®Google Scholar
• DOI T, KOIZUMI W, SIENA S et al.: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:1036 (Abstract).
   Google Scholar
• KORTMANSKY J, SCHWARTZ GK: Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. (2003) 21(6):924-936.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK, ILSON D, SALTZ L et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. (2001) 19(7):1985-1992.
   PubMed Web of Science ®Google Scholar
• SATO S, KAJIYAMA Y, SUGANO M et al.: Alvocidib (flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Surg. Oncol. (2006) 15(2):107-113.
   PubMed Web of Science ®Google Scholar
• RAJU U, ARIGA H, KOTO M et al.: Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependant kinases. Radiother. Oncol. (2006) 80(2):185-191.
   PubMed Web of Science ®Google Scholar
• DIPETRILLO T, MILAS L, EVANS D et al.: Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a Phase I study. Am J. Clin. Oncol. (2006) 29(4):376-379.
   PubMed Web of Science ®Google Scholar
• BODDY AV, PLUMMER ET, TODD R et al.: A Phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3- and 2-weekly schedules. Clin. Cancer Res. (2005) 11(21):7834-7840.
   PubMed Web of Science ®Google Scholar
• AJANI JA, SAFRAN H, BOKEMEYER C et al.: A multi-center Phase II study of BMS-247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest. New Drugs (2006) 24(5):441-446.
   PubMed Web of Science ®Google Scholar
• BIAMONTE MA, SHI J, HONG K et al.: Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. (2006) 49(2):817-828.
   PubMed Web of Science ®Google Scholar
• YU J, LEUNG WK, EBERT MP et al.: Increased expression of surviving in gastric cancer patients and first degree relatives. Br. J. Cancer (2002) 87(1):91-97.
   PubMed Web of Science ®Google Scholar
• LEE GH, JOO YE, CHUNG IJ et al.: Expression of survivn in gastric cancer and its relationship with tumor angiogenesis. Eur. J. Gastroenterol. Hepatol. (2006) 18(9):957-963.
   PubMed Web of Science ®Google Scholar
• WACHECK C, CEJKA D, SEIGHART W et al.: Mcl-1 is a relavent molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol. Ther. (2006) 5(10):1348-1354.
   PubMed Web of Science ®Google Scholar
• OSAKI M, KASE S, ADACHI K, TAKEDA A, HASHIMOTO K, ITO H: Inhibition of the Pl3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J. Cancer Res. Clin. Oncol. (2004) 130(1):8-14.
   PubMed Web of Science ®Google Scholar
• ZHANG X, YASHIRO M, REN J, HIRAKAWA K: Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol. Rep. (2006) 16(3):563-568.
   PubMed Web of Science ®Google Scholar
• POZZO C, BARONE C, SZANTO J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric-junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. (2004) 15(12):1773-1781.
   PubMed Web of Science ®Google Scholar
• KANG Y, KANG WK, SHIN DB et al.: Randomized Phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S):LBA4018.
   Google Scholar
• DANK M, ZALUSKI J, BARONE C et al.: Randomized Phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1st-line advanced gastric cancer patients. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S, Part I of II):4003.
   Google Scholar